


李 婷



職稱及職位：教授、博士生導師、人工智能交叉應用研究院副院長

學院/部門：中藥機制與質量研究全國重點實驗室

人工智能交叉應用研究院

電郵地址： tli@must.edu.mo

電話：(853) 8897 2401

傳真：(853) 2888 0091

辦公室：L504

郵寄地址：澳門氹仔偉龍馬路澳門科技大學

主要研究方向

- 1) 採用多組學技術研究炎症及自身免疫性疾病的發病機制；
- 2) 藥物作用新機制及新靶點研究；
- 3) 人工智能與新藥研發

簡介

李婷教授，博士，博士生導師，於 2010 年畢業於香港浸會大學，取得博士學位並進行博士後研究，2011 年 9 月加入澳門科技大學中藥機制與質量研究全國重點實驗室、澳門藥物及健康應用研究院擔任助理教授，後被晉升為副教授及教授。已在 *Signal Transduct Target Ther.*, *Cell reports Medicine*, *Acta Pharmaceutica Sinica B (cover story)*, *Pharmacological Research*, *Free Radical Biological Medicine*, 以及 *Angew Chem Int Ed Engl.* 等雜誌發表 SCI 學術論文 70 餘篇 授權國際發明專利 10 項 (美國專利 3 項)，中國發明專利 1 項；獲教育部自然科學獎一等獎 (2014 及 2018 年)，澳門科學技術獎一等獎 (2016 年) 及二等獎 (2022 年)，中國生物物理學會女科學家優秀科研成果三等獎 (2023 年，個人獎) 等多項獎項。作為課題負責人，獲國家重點研發計畫“政府間國際科技創新合作”，澳門科技發展基金等多項資助，金額超過 1500 萬元澳門幣。李博士亦為 WHO 傳統醫學合作中心 (澳門) 專家，世界中醫藥學會聯合會中藥免疫專業委員會常務理事，中國生物醫學工程學會免疫治療工程分會委員，中國抗炎免疫藥學專業委員會委員，中國

中西結合學會臨床藥理與毒理專業委員會理事，並擔任 MedComm - Future Medicine 副主編及 Frontiers in Immunology, Microstructures 學術雜誌編委等多項學術兼職。

工作履歷

2026.3-今	澳門科技大學人工智能交叉應用研究院，副院長
2023.7-今	澳門科技大學中藥機制與質量研究全國重點實驗室，教授
2023.7-2024.1	瑞典卡洛琳斯卡醫學院，訪問教授
2016.7-2023.6	澳門科技大學中藥機制與質量研究全國重點實驗室，副教授
2011.9-2016.6	澳門科技大學中藥機制與質量研究全國重點實驗室，助理教授
2010.6-2011.8	香港浸會大學 博士後研究員
2005.9-2006.12	香港浸會大學 研究助理

講授課程

本科：藥理學、微生物與免疫學、分子生物學與生物化學、中藥藥理學、中藥藥理學實驗

研究生：藥理學實驗方法及設計

負責承擔的科研項目項目

1. 2026.01-2029.01 治療多發性硬化症新靶點 HPGDS 的發現與驗證研究
(澳門科學技術發展基金-國際合作項目，項目編號 0007/2025/AIJ，澳門幣 3,236,000.00，負責人)
2. 2024.9-2026.8 ApoC3 蛋白作為多囊卵巢綜合征胰島素抵抗預警標記物的技術研發及臨床應用
(澳門科學技術發展基金-廣東省聯合項目，項目編號 0043/2024/AGJ，澳門幣 1,170,000.00，負責人)
3. 2023.11-2026.10 靶向 Th17 細胞治療自身免疫性疾病的創新藥物研究
(國家重點研發計畫“政府間國際科技創新合作”，項目編號 0018/2023/AMJ，澳門幣 2,064,000，負責人)
4. 2022.07-2025.07 融合臨床、單細胞和多組學數據的人工智慧技術在結直腸癌的精准診療的研究
(澳門科學技術發展基金，項目編號 0003/2021/AKP，澳門幣 7,330,000，子課題負責人)
5. 2021.04-2022.04 基於 Spike/ACE2 互作介面探索 019-nCoV 治療策略

- (澳門科學技術發展基金, 項目編號 0058/2020/A, 澳門幣 385,000, 負責人)
6. 2020.09-2022.09 高等院校青年科研人員國際培養專項資助
(澳門科學技術發展基金, 項目編號 011/AIJ/2020, 澳門幣 180,000, 負責人)
 7. 2018.10-2021.11 基於 IKK β knock-in 小鼠研究炎症中蛋白降解的穩態調控機制及藥物作用新靶標
(澳門科學技術發展基金, 項目編號 0017/2018/A1, 澳門幣 2,145,000, 負責人)
 8. 2015.04-2015.12 全自動磁性細胞分選儀 autoMACS Pro
(澳門科學技術發展基金, 項目編號 025/2014/SB, 澳門幣 612,110, 負責人)
 9. 2014.05-2017.04 來源於中藥的小分子化合物基於 ROR γ t 靶標對 Th17 及自身免疫疾病的抑制作用及機理研究
(澳門科學技術發展基金, 項目編號 081/2013/A3, 澳門幣 1,810,400, 負責人)
 10. 2012.05-2014.12 中藥二氫黃酮化合物與地塞米松合用時對免疫器官的保護作用及協同抗炎的機理研究
(澳門科學技術發展基金, 項目編號 065/2011/A3, 澳門幣 1,736,400, 負責人)
 11. 2012.1-2012.12 紫草素通過抑制 IKK β -I κ B α -NF- κ B 及 MAPK 信號轉導通路對 T 細胞活化的研究
(澳門基金會, 項目編號 0213, 澳門幣 53,000.00, 負責人)

科研獲獎

1. 2023 年中國生物物理學會女科學家優秀科研成果三等獎 (個人獎)
2. 2022 年度澳門特別行政區科學技術獎-自然科學獎二等獎
項目名稱: 基於人工智能和多組學的新型冠狀病毒感染的機制和診治的關鍵技術研究
3. 2018 年度國家教育部高等學校科學研究優秀成果獎-自然科學獎一等獎
項目名稱: 抑制細胞增殖與分化異常的新機制研究
4. 2017 澳門科技大學中珠醫療生命科學科研一等獎 (個人獎)
5. 2016 澳門科技大學中銀最佳學術研究獎 (個人獎)
6. 2016 年度澳門特別行政區科學技術獎-自然科學獎一等獎
項目名稱: 類風濕關節炎的發病新機制和治療新途徑
7. 2014 年度國家教育部高等學校科學研究優秀成果獎-自然科學獎一等獎

項目名稱：中醫藥整體治療的網路調節機理研究

指導研究生所獲獎勵

1. 劉娟 2020 年澳門研究生（博士）科技研發獎
2. 劉娟 2020 年澳門高等院校博士後專項資助計畫
3. 楊芬 2016 世界生命科學大會 最佳海報獎

學術雜誌編委

1. Frontiers in Immunology 編委
2. Microstructures 編委
3. MedComm - Future Medicine 副主編

學術兼職

1. WHO 傳統醫學合作中心（澳門）專家
2. 世界中醫藥學會聯合會中藥免疫專業委員會 常務理事
3. 中國生物醫學工程學會免疫治療工程分會 委員
4. 中國抗炎免疫藥學專業委員會 委員
5. 中國中西結合學會臨床藥理與毒理分會 委員

授權專利

- 1) Novel binding site of IKK-beta. Australian Innovation Patent No. 2013101130; Granted on 5 Sept 2013.
- 2) Development of a new formula overcoming thymus atrophy with concomitantly enhancement of anti-inflammatory effect of dexamethasone, Australian Innovation Patent No. 2014100379; Granted on 1 May 2014.
- 3) Development of a new formula overcoming thymus atrophy with concomitantly enhancement of anti-inflammatory effect of dexamethasone, US Utility Patent No. 9,018,196; Granted on 28 Apr 2015.
- 4) Isoliquiritigenin suppresses human T lymphocyte activation via targeting on cysteine 46 of IκBα Kinase. Australian Innovation Patent No. 2015100662; Granted on 28 May 2015.

- 5) Limonoids for treating autoimmune diseases. Australian Innovation Patent No. 2017100026; Granted on 9 Jan 2017.
- 6) Method to treat anaphylactoid reaction; Australian Innovation Patent No. 2017100973; Granted on 17 July 2017.
- 7) Method of treating rheumatoid arthritis. Australian Innovation Patent No. 2017101103; Granted on 14 August 2017.
- 8) Method of treating an autoimmune disease. Australian Innovation Patent No. 2017101742; Granted on 12 Dec 2017.
- 9) Limonoids for treating autoimmune diseases. US Utility Patent No 9,901,566; Granted on 27 Feb 2018.
- 10) Transgenic model for delay-type hypersensitivity (DTH) and use thereof, US Utility Patent No 9,955,676; Granted on 2 May 2018.
- 11) Application of limonoids in autoimmune diseases, China Patent Publication No. CN 108371659 B Granted on 28 Oct, 2022

論文發表

- 1) Zhenghao Li, Wende Deng, Lanxuan Yang, Changheng Tang, Jian-Min Yue, Olivia Monteiro, and Daniel Baptista-Hon, **Li T**, Lipid metabolism in homeostasis and disease, *Signal Transduct Target Ther. In Press* [IF: 52.7, ranked 1st in 319 journals (0.2%) of BIOCHEMISTRY & MOLECULAR BIOLOGY]
- 2) Lee-Fong Yau, Meng-Lan Yu, Tian-Tian Tong, Long-Bo Bai, Yu-Hang Zhang, Ya-Ling Yu, **Li T**[#], Zhi-Hong Jiang[#], Nanoliposome strategy for improving bioavailability and anti-acute alcoholic effects of dihydromyricetin through ginsenoside incorporation, *Food Bioscience*, (2026) 108143. (#co-corresponding author). [IF: 5.9, ranked 32rd in 182 journals (17.6%) of category FOOD SCIENCE & TECHNOLOGY]
- 3) Li Y, Tao Y, Zhao Z, Zhong P, Zhong L, Yang H, Yu M, Liu S, Lei K, Zhao Q, Wang R, Wang J, Zeng Q, Kuang S, **Li T**, Long COVID as an independent predictor of myasthenia gravis exacerbation: A prospective cohort study integrating machine learning for risk stratification, *Respir Med.* 2025 Nov 29;251:108554. [IF: 3.1, ranked 33rd in 108 journals (30.6%) of category RESPIRATORY SYSTEM]
- 4) Deng W., **Li T**. Skin as an autonomous immune organ: Antibody production and host protection, *Acta Pharm Sin B.* 2025 May;15(5):2795-2797.[IF: 14.6, ranked 3rd in 353 journals (0.71%) of category PHARMACOLOGY & PHARMACY]
- 5) Deng WD*, Liu JY* Tang CH* Li ZH, Qiu Y, Zhou H, Yang LX, **Li T**. Critical role of skin in pathogenesis: bidirectional crosstalk between skin and multiple organs. *MedComm - Future Medicine.* 2025. 4:e70020 (Cover story, Highlighted by EurekAlert!)
- 6) Liu F, Niu Y, Zhang Q, Wang K, Dong Z, Wong IN, Cheng L, **Li T**, Duan L, Li K, Li G, Hou TW, Fok M, Luo H, Chen X, Zhang K, Yin Y. A foundational architecture for AI agents in healthcare. *Cell Rep Med.* 2025 Oct 21;6(10):102374. [IF: 10.6, ranked 15th in 195 journals (7.7% category MEDICINE, RESEARCH & EXPERIMENTAL)]
- 7) Liu F., Zhou H., Wang K., Yu Y., Gao Y., Sun Z., Liu S., Sun S., Zou Z., Li Z., Li B., Miao H., Liu

Y., Hou T., Fok M., Patil N. G., Xue K., **Li T.**, Oermann E., Yin Y., Zhang K. MetaGP: A generative foundation model integrating electronic health records and multimodal imaging for addressing unmet clinical needs. *Cell reports Medicine*, 2025;15:6(4):102056. ([IF: 10.6, ranked 15th in 195 journals (7.7% category MEDICINE, RESEARCH & EXPERIMENTAL)]

8) Lok L.S.C., Sarkar S., Lam C.C.I., Law C.F., Chau S.T., Leung C.Y.T., Cheang W.H., **Li T.**, Monteiro O. and Baptista-Hon D.T. Long COVID across SARS-CoV-2 variants: Clinical features, pathogenesis, and future directions. *Medcomm - Future Medicine* (2024)

9) Gao S, Yang C, Huang B, Yang L, Lu L, Yang H, **Li T**[#], Pan Q[#]. Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis. *Front Immunol.* 2025 Jan 10;15:1472292. (#co-corresponding author). [IF: 5.9, ranked 42nd in 183 journals (22.68%) of category IMMUNOLOGY]

10) Guo ZY, Tang YQ, Zhang ZB, Liu J, Zhuang YX, **Li T.** COVID-19: from immune response to clinical intervention. *Precis Clin Med.* 2024 Jul 18;7(3):pbae015. [IF: 5.0, ranked 45th in 195 journals (22.8%) of category MEDICINE, RESEARCH & EXPERIMENTAL]

11) Wang MM, Zhao Y, Liu J, Tang Y, Fan R, Guo Z, **Li T.** The role of the cGAS-STING signaling pathway in viral infections, inflammatory and autoimmune diseases. *Acta Pharmacol Sin*, 2024 Jun 1. [IF: 8.4, ranked 15th in 353 journals (4.1%) of category PHARMACOLOGY & PHARMACY]

12) Wang X, Li J, Chen R, **Li T.**, Chen M. Active Ingredients from Chinese Medicine for Combination Cancer Therapy. *Int J Biol Sci.* 2023 Jul 9;19(11):3499-3525. [IF: 10.0, ranked 26th in 320 journals (8.1%) of category BIOCHEMISTRY & MOLECULAR BIOLOGY]

13) Ji KL, Tang YQ, Guo ZY, GongPan PC, Sun P, Lu JM, Dai MY, **Li T.** Natural Geranylated Sulfur-Containing Amides with Inhibitory Effect on Th17 Differentiation. *Chem Biodivers.* 2023 Jun;20(6):e202300373. doi: 10.1002/cbdv.202300373. Epub 2023 May 22. [IF: 2.5, ranked 123rd in 239 journals (51.5%) of category CHEMISTRY, MULTIDISCIPLINARY]

14) Zhao Y, Jin H, Lei K, Bai LP, Pan H, Wang C, Zhu X, Tang Y, Guo Z, Cai J, **Li T.** Oridonin inhibits inflammation of epithelial cells *via* dual-targeting of CD31 Keap1 to ameliorate acute lung injury. *Front Immunol.* 2023 Apr 6;14:1163397. [IF: 5.9, ranked 42nd in 183 journals (22.68%) of category IMMUNOLOGY]

15) Zhang Q, Hao S, Li L, Liu M, Huo C, Bao W, Cheng H, Fung H, Wong T, Wu W, Leung P, Wang S, **Li T.**, Zhang G, Li M, Zhao Z, Jia W, Bian Z, Mitchison T, Zhang J, Lyu A, Han Q. M cells of mouse and human Peyer's patches mediate the lymphatic absorption of an Astragalus hyperbranched heteroglycan. *Carbohydr Polym.* 2022 Nov 15;296:119952. [IF: 12.5, ranked 1st in 57 journals (1.8%) of category POLYMER SCIENCE]

16) Wang Y, Deng W, Liu J, Yang Q, Chen Z, Su J, Xu J, Liang Q, **Li T.**, Liu L, Li X. IKK β increases neuropilin-2 and promotes the inhibitory function of CD9⁺ Bregs to control allergic diseases. *Pharmacol Res.* 2022 Nov;185:106517. [IF: 10.334, ranked 15th in 279 journals (5.38%) of category PHARMACOLOGY & PHARMACY]

17) Zhang Q, Li L, Hao S, Liu M, Huo C, Wu J, Liu H, Bao W, Zheng H, Li Z, Cheng H, Fung H, Wong T, Leung P, Wang S, **Li T.**, Zhang G, Li M, Zhao Z, Jia W, Bian Z, Mitchison T, Zhang J, Lyu A, Han Q, Sun H. A lymphatic route for a hyperbranched heteroglycan from Radix Astragali to trigger immune responses after oral dosing. *Carbohydr Polym.* 2022 Sep 15;292:119653 [IF: 12.5, ranked 1st in 57 journals (1.8%) of category POLYMER SCIENCE]

18) Wang M, Zhao Y, Liu J, **Li T.** SARS-CoV-2 modulation of RIG-I-MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches. *MedComm Futur Med.* 2022 Sep;1(2):e29.

- 19) Zheng Z, Xu T, Liu Z, Tian W, Jiang ZH, Zhu GY, **Li T**, Gao J, Bai LP. Cryptolepine suppresses breast adenocarcinoma via inhibition of HIF-1 mediated glycolysis. *Biomed Pharmacother.* 2022 Sep;153:113319. [IF: 7.5, ranked 19th in 352 journals (5.3%) of category PHARMACOLOGY & PHARMACY]
- 20) Liu J, Zhuang YX, Wu J, Wu Q, Liu MX, Zhao Y, Liu ZQ, Wang CY, Lu LL, Meng YJ, Lei KW, Li XJ, Wu QB, Leung ELH, Guo ZY, Liu L[#], **Li T**[#], IKK β mediates homeostatic function in inflammation via competitively phosphorylating AMPK and I κ B α . *Acta Pharm Sin B.* 2022 Feb;12(2):651-664. (#corresponding author, cover story) [IF: 14.8, ranked 6th in 352 journals (1.6%) of category PHARMACOLOGY & PHARMACY]
- 21) Xiao RP, Lei KW, Kuok HH, Deng WD, Zhuang YX, Tang YQ, Guo ZY, Qin HY[#], Bai L-P[#], **Li T**[#], Synthesis and identification of lithocholic acid 3-sulfate as ROR γ t ligand to inhibit Th17 cell differentiation. *J Leukoc Biol.* 2022 Feb 21. doi: 10.1002. (#corresponding author) [IF: 3.1, ranked 31st in 98 journals (31.1%) of category HEMATOLOGY]
- 22) Huang X, Chen L, Zhang Y, Zhou S, Cai HH, **Li T**, Jin H, Cai J, Zhou H, Pi J. GE11 Peptide Conjugated Liposomes for EGFR-Targeted and Chemopreventive Combined Anticancer Therapy. *Bioinorg Chem Appl.* 2021 Mar 31;2021:5534870. [IF: 4.724, ranked 6th in 46 journals (13.04%) of category CHEMISTRY, INORGANIC & NUCLEAR]
- 23) Wang J, Xu C, Chen Y, Shao L, **Li T**, Fan X, Yu L, Zhang R, Chen B, Chen H, Sui X, Leung EL, Wu Q. β -elemene enhances the antitumor activity of erlotinib by inducing apoptosis through AMPK and MAPK pathways in TKI-resistant H1975 lung cancer cells. *J Cancer.* 2021 Feb 22;12(8):2285-2294. [IF: 4.478, ranked 115th in 245 journals (46.73%) of category ONCOLOGY]
- 24) Zheng Z, Zhou Z, Zhang Q, Zhou X, Yang J, Yang MR, Zhu GY, Jiang ZH, **Li T**, Lin Q, Bai LP. Non-classical cardenolides from *Calotropis gigantea* exhibit anticancer effect as HIF-1 inhibitors. *Bioorg Chem.* 2021 Feb 18;109: 104740. [IF: 1.254, ranked 52nd in 63 journals (81.75%) of category CHEMISTRY, ORGANIC]
- 25) Ge ZP, Fan YY, Deng WD, Zheng CY, **Li T**, Yue JM. Cephalodiones A-D: Compound Characterization and Semisynthesis by [6+6] Cycloaddition. *Angew Chem Int Ed Engl.* 2021 Feb 2. doi: 10.1002/anie.202015332. [IF: 16.823, ranked 15th in 179 journals (8.1%) of category CHEMISTRY, MULTIDISCIPLINARY]
- 26) Liao K, Su X, Lei K, Liu Z, Lu L, Wu Q, Pan H, Huang Q, Zhao Y, Wang M, Cai J, Liu L[#], **Li T**[#]. Sinomenine protects bone from destruction to ameliorate arthritis via activating p62Thr269/Ser272-Keap1-Nrf2 feedback loop. *Biomed Pharmacother.* 2021 Jan 1;135:111195. (#co-corresponding author) [IF: 7.5, ranked 19th in 352 journals (5.3%) of category PHARMACOLOGY & PHARMACY]
- 27) Huang X, Cai H, Zhou H, **Li T**, Jin H, Evans CE, Cai J, Pi J. Cobalt oxide nanoparticle-synergized protein degradation and phototherapy for enhanced anticancer therapeutics. *Acta Biomater.* 2021 Feb;121:605-620. [IF: 10.633, ranked 13th in 98 journals (12.76%) of category ENGINEERING, BIOMEDICAL]
- 28) Wu Q, Yao X, Chen H, Liu Z, **Li T**, Fan X, Zhang G, Yu L, Chen M, Xu C, Zhang R, Chen B, Sui X, Leung EL. Long-term aspirin use for primary cancer prevention: An updated systematic review and subgroup meta-analysis of 29 randomized clinical trials. *J Cancer.* 2020 Sep 14;11(21):6460-6473. [IF: 4.478, ranked 115th in 245 journals (46.73%) of category ONCOLOGY]
- 29) Ji KL, Fan YY, Kuok HH, Liu QF, **Li T**, and Jian-Min Yue, Macrocyclic Nonapeptides Incorporating Uncharacterized Amino Acids with Inhibitory Effects on Th17 Differentiation. *CCS Chemistry.* 2020, 3 (2): 844-858.

- 30) Xu C, Yao XJ, **Li T**, Wang J, An B, Wang J, Sui XB, Leung ELH, Wu QB, Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer. *Transl Cancer Res.* 2020 Apr;9(4):2875-2883. [IF: 0.496, ranked 242nd in 245 journals (98.57%) of category CHEMISTRY, MULTIDISCIPLINARY]
- 31) Chen H, Yao X, **Li T**, Lam CW, Zhang R, Zhang H, Wang J, Zhang W, Leung EL, Wu Q. Compound Kushen injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines. *J Cancer.* 2020 Jan 20;11(7):1883-1898. [IF: 4.478, ranked 115th in 245 journals (46.73%) of category ONCOLOGY]
- 32) Zou B*, Zhang Y*, **Li T***, Liu J, Deng W, Tan Y, Yang Q, Ding Z, Liao K, Xu J, Pan H, Li X, Liu L. A mutation of cysteine 46 in IKK- β promotes mPGES-1 and caveolin-1 expression to exacerbate osteoclast differentiation and osteolysis. *Biochem Pharmacol.* 2019 Dec 13:113762. (*co-first author). [IF: 5.6, ranked 33rd in 352 journals (9.38%) of category PHARMACOLOGY & PHARMACY]
- 33) Chen H, Yao X, **Li T**, Lam CW, Zhang H, Wang J, Zhang W, Leung EL, Wu Q. Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A protocol for meta-analysis of randomized clinical trials following the PRISMA guidelines. *Medicine (Baltimore).* 2019 Dec;98(52):e18552. [IF:1.817, ranked 123th in 172 journals (71.51%) of category MEDICINE, GENERAL & INTERNAL]
- 34) Chen H, Yao X, Liu Z, **Li T**, Xu C, Wang J, Sui X, Leung EL, Wu Q. Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore).* 2019 Sep;98(39):e17350. [IF:1.817, ranked 123th in 172 journals (71.51%) of category MEDICINE, GENERAL & INTERNAL]
- 35) Wu Q, Chen H, Yao X, **Li T**, Xu C, Wang J, Sui X, Leung EL. Long-term aspirin use for cancer primary prevention: A protocol for updated systematic review and subgroup meta-analysis of randomized clinical trials. *Medicine (Baltimore).* 2019 Sep;98(39):e17382. [IF:1.817, ranked 123th in 172 journals (71.51%) of category MEDICINE, GENERAL & INTERNAL]
- 36) Chen Q, Liu J, Zhuang Y, Bai LP, Yuan Q, Zheng S, Liao K, Khan MA, Wu Q, Luo C, Liang L, Wang H, **Li T**[#]. Identification of an IKK β inhibitor for inhibition of inflammation in vivo and in vitro. *Pharmacol Res.* 2019 Aug 31:104440. (#co-corresponding author). . (#co-corresponding author). [IF: 10.5, ranked 13rd in 352 journals (3.6%) of category PHARMACOLOGY & PHARMACY]
- 37) Pan H, Guo R, Ju Y, Wang Q, Zhu J, Xie Y, Zheng Y, **Li T**, Liu Z, Lu L, Li F, Tong B, Xiao L, Xu X, Leung EL, Li R, Yang H, Wang J, Zhou H, Jia H, Liu L. A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. *Microbiome.* 2019 Jul 17;7(1):107. [IF: 16.837, ranked 9th in 137 journals (6.57%) of category MICROBIOLOGY]
- 38) Liu J, Bai LP, Yang F, Yao XJ, Lei K, Lam, Christopher Wai Kei; Wu QB, Zhuang YX, Xiao RP, Liao KS, Kuok HH, **Li T**[#], Liu L[#]. Potent antagonists of ROR γ t, cardenolides from *Calotropis gigantea*, exhibit discrepant effects on the differentiation of T lymphocyte subsets. (#co-corresponding author). *Mol Pharm.* 2019 Feb 4;16(2):798-807. (#co-corresponding author). [IF: 4.5, ranked 64th in 352 journals (18.18%) of category PHARMACOLOGY & PHARMACY]
- 39) Fan DS, **Li T**, Zheng Z, Zhu GY, Yao X, Jiang ZH, Bai LP. Macrolide sesquiterpene pyridine alkaloids from the stems of *Tripterygium regelii*. *J Nat Med.* 2018 Aug 13. doi: 10.1007/s11418-018-1232-8. [IF: 3.192, ranked 40th in 63 journals (63.49%) of category CHEMISTRY, MEDICINAL]
- 40) **Li T***, Yan F*, Meng X, Wang J, Ting Kam RK, Zeng X, Liu Z, Zhou H, Yang F, Ren R, Liao K, Liu L. Improvement of glucocorticoid-impaired thymus function by dihydromyricetin via

up-regulation of PPAR γ -associated fatty acid metabolism. *Pharmacol Res.* 2018 Nov;137:76-88. (*co-first author). [IF: 10.5, ranked 13rd in 352 journals (3.6%) of category PHARMACOLOGY & PHARMACY]

41) Yang F Su X, Pi J, Liao K, Zhou H, Sun Y, Liu J, Guo X, Jiang J, Jin H, Cai J, **Li T[#]**, Liu L[#], Atomic force microscopy technique used for assessment of the anti-arthritic effect of licochalcone A via suppressing NF- κ B activation, *Biomed Pharmacother.* 2018 Jul;103:1592-1601. (#co-corresponding author). [IF: 7.5, ranked 19th in 352 journals (5.3%) of category PHARMACOLOGY & PHARMACY]

42) Pan H, Guo R, Zhu J, Wang Q, Ju Y, Xie Y, Zheng Y, Wang Z, **Li T**, Liu Z, Lu L, Li F, Tong B, Xiao L, Xu X, Li R, Yuan Z, Yang H, Wang J, Kristiansen K, Jia H, Liu L. A gene catalogue of the Sprague-Dawley rat gut metagenome. *Gigascience.* 2018 May 1;7(5). [IF: 7.658, ranked 13th in 74 journals (17.57%) of category MULTIDISCIPLINARY SCIENCES]

43) Su X*, **Li T***, Liu Z, Huang Q, Liao K, Ren R, Lu L, Qi X, Wang M, Chen J, Zhou H, Leung EL, Pan H, Liu J, Wang H, Huang L, Liu L. Licochalcone A activates Keap1-Nrf2 signaling to suppresses arthritis via phosphorylation of p62 at serine 349. *Free Radic Biol Med.* 2018 Feb 1;115:471-483. (*co-first author). [IF: 8.2, ranked 14th in 191 journals (7.1%) of category ENDOCRINOLOGY & METABOLISM]

44) Jin H, Pi J, Zhao Y, Jiang J, **Li T**, Zeng X, Yang P, Evans CE, Cai J. EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy. *Nanoscale.* 2017 Nov 2;9(42):16365-16374. [IF: 8.307, ranked 68th in 414 journals (16.43%) of category MATERIALS SCIENCE, MULTIDISCIPLINARY]

45) Zhou H, Liu JX, Luo JF, Cheng CS, Leung EL, Li Y, Su XH, Liu ZQ, Chen TB, Duan FG, Dong Y, Zuo YH, Li C, Lio CK, **Li T**, Luo P, Xie Y, Yao XJ, Wang PX, Liu L. Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis. *Biochem Pharmacol.* 2017 Oct 15;142:133-144. [IF: 6.100, ranked 46th in 279 journals (16.31%) of category PHARMACOLOGY & PHARMACY]

46) Huang L.F., Dong Y., Wu J. L., Wang P.X., Zhou H., **Li T[#]** and Liu L[#], Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF- κ B signaling. *Pharmacol Res.* 2017 Nov;125(Pt B):150-160. (#co-corresponding author). [IF: 10.5, ranked 13rd in 352 journals (3.6%) of category PHARMACOLOGY & PHARMACY]

47) Chen J.Y., Zhu G.Y., Su X.H., Wang R., Liu J., **Li T[#]** and Liu L[#], 7-Deceaylgedunin suppresses proliferation of macrophages and inflammation through activation of Keap1/Nrf2/HO-1 signaling. *Oncotarget.* 2017 Jul 5;8(33):55051-55063. (#co-corresponding author). [IF 5.168, ranked 44th in 214 journals (20%) of category ONCOLOGY]

48) Chen Y. N., Li H. F., Li M. F., Niu S., B., Wang J. X., Shao H., W., **Li T[#]**, Wang H[#]. Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF- κ B signaling pathways. *Journal of Ethnopharmacology.* 2017 Feb 20. pii: S0378-8741(16)31471-4. (#co-corresponding author) [IF: 5.4, ranked 5th in 45 journals (10.0%) of category INTEGRATIVE & COMPLEMENTARY MEDICINE]

49) Pan H, Li R, **Li T**, Wang J, Liu L, Whether Probiotic Supplementation Benefits Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. *Engineering.* 2017 February, 3 (1):115-121. [IF: 12.834, ranked 1st in 92 journals (1.09%) of category ENGINEERING, MULTIDISCIPLINARY]

50) Yan FG, Yang F, Wang R, Yao XJ, Bai LP, Zeng X, Huang JJ, Wong VK, Lam CW, Zhou H, Su XH, Liu J, **Li T[#]**, Liu L[#] Isoliquiritigenin suppresses human T lymphocyte activation via covalently binding cysteine 46 of I κ B Kinase. *Oncotarget.* 2017 May 23;8(21):34223-34235. (#co-corresponding

author). [IF 5.168, ranked 44th in 214 journals (20%) of category ONCOLOGY]

51) Su X, Huang Q, Chen J, Wang M, Pan H, Wang R, Zhou H, Zhou Z, Liu J, Yang F, **Li T**[#], Liu L[#] Calycosin suppresses expression of pro-inflammatory cytokines via the activation of p62/Nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts. *Pharmacol Res.* 2016 Nov;113 (Pt A):695-704. (#co-corresponding author). [IF: 10.5, ranked 13rd in 352 journals (3.6%) of category PHARMACOLOGY & PHARMACY]

52) Fan DS, Zhu GY, **Li T**, Jiang ZH, Bai LP. Dimacrolide Sesquiterpene Pyridine Alkaloids from the Stems of *Tripterygium regelii*. *Molecules.* 2016, 21(9), 1146. [IF: 4.927, ranked 114th in 297 journals (38.38%) of category CHEMISTRY, MULTIDISCIPLINARY]

53) Wang R, Pi J, Su X, Liu J, Zeng X, Wong I, Huang L, Zhou H, Cai J, **Li T**[#], Liu L[#]. Dihydromyricetin suppresses inflammatory responses in vitro and in vivo through inhibition of IKK β activity in macrophages. *Scanning.* 2016 Aug 3. (#co-corresponding author). IF: 1.750, ranked 43th in 64 journals (67.19%) of category INSTRUMENTS & INSTRUMENTATION]

54) Jin H, Pi J, Yang F, Jiang J, Wang X, Bai H, Shao M, Huang L, Zhu H Yang P, Li L, **Li T**, Cai JY, Chen ZW. Folate-Chitosan Nanoparticles Loaded with Ursolic Acid Confer Anti-Breast Cancer Activities in vitro and in vivo. *Sci Rep.* 2016 Jul 29;6:30782. [IF: 4.3997, ranked 19th in 74 journals (25.68%) of category MULTIDISCIPLINARY SCIENCES]

55) Huang LF, Pi J, Wu JL, Zhou H, Cai JY, **Li T**[#], Liu L[#], A rapid and sensitive assay based on particle analysis for cell degranulation detection in basophils and mast cells. *Pharmacol Res.* 2016 Jun 21;111:374-383. (#co-corresponding author). . (#co-corresponding author). [IF: 10.5, ranked 13rd in 352 journals (3.6%) of category PHARMACOLOGY & PHARMACY]

56) Parhira S, Zhu GY, **Li T**, Liu L, Bai LP, Jiang ZH. Inhibition of IKK- β by epidioxysterols from the flowers of *Calotropis gigantea* (Niu jiao gua). *Chin Med.* 2016 Mar 2;11:9. [IF: 4.546, ranked 6th in 30 journals (20%) of category INTEGRATIVE & COMPLEMENTARY MEDICINE]

57) **Li T**^{*}, Wong VK^{*}, Jiang ZH, Jiang SP, Liu Y, Wang TY, Yao XJ, Su XH, Yan FG, Liu J, Leung EL, Yi XQ, Wong YF, Zhou H, Liu L. Mutation of cysteine 46 in IKK-beta increases inflammatory responses. *Oncotarget.* 2015 Oct 13;6(31):31805-19. (*co-first author). [IF 5.168, ranked 44th in 214 journals (20%) of category ONCOLOGY]

58) Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y, Lan Z, Chen B, Li Y, Zhong H, Xie H, Jie Z, Chen W, Tang S, Xu X, Wang X, Cai X, Liu S, Xia Y, Li J, Qiao X, Al-Aama JY, Chen H, Wang L, Wu QJ, Zhang F, Zheng W, Li Y, Zhang M, Luo G, Xue W, Xiao L, Li J, Chen W, Xu X, Yin Y, Yang H, Wang J, Kristiansen K, Liu L, **Li T**, Huang Q, Li Y, Wang J. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat Med.* 2015 Aug;21(8):895-905. [IF: 87.224, ranked 1st in 297 journals (0.34%) of category BIOCHEMISTRY & MOLECULAR BIOLOGY]

59) Huang L, **Li T**, Zhou H, Qiu P, Wu J, Liu L. Sinomenine potentiates degranulation of RBL-2H3 basophils via up-regulation of phospholipase A2 phosphorylation by Annexin A1 cleavage and ERK phosphorylation without influencing on calcium mobilization. *Int Immunopharmacol.* 2015 Oct;28(2):945-51. [IF: 4.7, ranked 54th in 352 journals (15.2%) of category PHARMACOLOGY & PHARMACY]

60) Wang R, Zhang CY, Bai LP, Pan HD, Shu LM, Kong AN, Leung EL, Liu L[#], **Li T**[#]. Flavonoids derived from liquorice suppress murine macrophage activation by up-regulating heme oxygenase-1 independent of Nrf2 activation. *Int Immunopharmacol.* 2015 Oct;28(2):917-24. (#co-corresponding author). . [IF: 4.7, ranked 54th in 352 journals (15.2%) of category PHARMACOLOGY & PHARMACY]

61) Leung EL, Wong VK, Jiang ZH, **Li T**, Liu L. Integrated network-based medicine: the role of

traditional Chinese medicine in developing a new generation of medicine. *Science*. 2014 Dec, 346 (6216 Suppl), S16-S18. [IF: 63.832, ranked 2nd in 74 journals (2.70%) of category MULTIDISCIPLINARY SCIENCES]

62) Pi J, **Li T**, Liu J, Su X, Wang R, Yang F, Bai H, Jin H, Cai J Detection of lipopolysaccharide induced inflammatory responses in RAW264.7 macrophages using atomic force microscope. *Micron*. 2014 Oct;65:1-9. [IF: 2.381, ranked 5th in 9 journals (55.56%) of category MICROSCOPY]

63) Wong VK*, **Li T***, Law BY, Ma ED, Yip NC, Michelangeli F, Law CK, Zhang MM, Lam KY, Chan PL and Liu L. Saikosaponin-d, a novel SERCA inhibitor induces autophagic cell death in apoptosis-defective cells. *Cell Death Dis*. 2013 Jul 11;4(7):e720. (*co-first author). [IF: 9.6, ranked 29th in 204 journals (14%) of category PHARMACOLOGY & PHARMACY]

64) **Li T**, Yan F, Wang R, Zhou H, Liu L. Shikonin Suppresses Human T Lymphocyte Activation through Inhibition of IKK β Activity and JNK Phosphorylation. *Evid Based Complement Alternat Med*. 2013;379536. [IF: 2.650, ranked 16th in 30 journals (48.33%) of category INTEGRATIVE & COMPLEMENTARY MEDICINE]

65) Ding R, Tang J, Gao H, **Li T**, Zhou H, Liu L, Yao XS. New methymycin derivatives of *Streptomyces venezuelae* ATCC 15439 and their inhibitory effects on human T cell proliferation mediated by PMA/ionomycin. *Arch Pharm Res*. 2012 Sep;35(9):1567-72. [IF: 6.010, ranked 49th in 279 journals (17.56%) of category PHARMACOLOGY & PHARMACY]

66) Zhu L, Lu JG, **Li T**, Zhu GY, Han QB, Hsiao WL, Liu L, Jiang ZH. Immunosuppressive decalin derivatives from red yeast rice. *J Nat Prod*. 2012 Apr 27;75(4):567-71. [IF: 4.803, ranked 84th in 279 journals (28.28%) of category PHARMACOLOGY & PHARMACY]

67) Yi XQ, **Li T**, Wang JR, Wong VK, Luo P, Wong IY, Jiang ZH, Liu L, Zhou H. Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. *Phytomedicine*. 2010 Nov;17(13):1006-15. [IF: 6.656, ranked 1st in 30 journals (3.33%) of category INTEGRATIVE & COMPLEMENTARY MEDICINE]

68) Wong VK, Cheung SS, **Li T**, Jiang ZH, Wang JR, Dong H, Yi XQ, Zhou H, Liu L. Asian ginseng extract inhibits in vitro and in vivo growth of mouse lewis lung carcinoma via modulation of ERK-p53 and NF- κ B signaling. *J Cell Biochem*. 2010 Nov 1;111(4):899-910. [IF: 4.481, ranked 136th in 297 journals (45.80%) of category BIOCHEMISTRY & MOLECULAR BIOLOGY]

69) **Li T**, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. *Biol Pharm Bull*. 2010;33(1):40-6. [IF: 1.7, ranked 265th in 352 journals (72.7%) of category PHARMACOLOGY & PHARMACY]

70) **Li T**, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation. *J Cell Biochem*. 2009 Sep 1;108(1):87-95. [IF: 2.8, ranked 187th in 319 journals (58.5%) of category BIOCHEMISTRY & MOLECULAR BIOLOGY]

71) Wong VK, Zhou H, Cheung SS, **Li T**, Liu L. Mechanistic study of saikosaponin-d (Ssd) on suppression of murine T lymphocyte activation. *J Cell Biochem*. 2009 May 15;107(2):303-15. [IF: 4.481, ranked 136th in 297 journals (45.80%) of category BIOCHEMISTRY & MOLECULAR BIOLOGY]